 |
72 Diseases |  |
11 Trials |
|
11 Trials |  |
447 News |  |
| «12345» |
- | Emestop (ramosetron hydrochloride) / Samyang Group
Clinical, Journal: Postoperative Nausea and Vomiting Prophylaxis: A Comparative Study of Ramosetron and Palonosetron in Patients Undergoing Laparoscopic Cholecystectomy - A Prospective Randomized Trial. (Pubmed Central) - Apr 30, 2019
The incidences of adverse effects were statistically insignificant between the groups. Prophylactic therapy with palonosetron is more effective than ramosetron for long-term prevention of PONV following laparoscopic cholecystectomy.
- | dexamethasone / generics, olanzapine / generics, palonosetron intravenous / generics
Clinical, Journal, CINV: A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Moderately Emetogenic Chemotherapy: Results of the Korean South West Oncology Group (KSWOG) Study. (Pubmed Central) - Apr 21, 2019
Prophylactic therapy with palonosetron is more effective than ramosetron for long-term prevention of PONV following laparoscopic cholecystectomy. Olanzapine combined with palonosetron and dexamethasone significantly improved QOL and vomiting control among previously untreated patients receiving MEC, although the efficacy was limited to the reduction of the frequency of CINV.
- | dexamethasone / generics, ondansetron / generics, palonosetron intravenous / generics
Clinical, Journal, Head-to-Head: A randomized, open-label non-inferiority study to compare palonosetron and ondansetron for prevention of acute chemotherapy-induced vomiting in children with cancer receiving moderate or high emetogenic chemotherapy. (Pubmed Central) - Mar 29, 2019
Olanzapine combined with palonosetron and dexamethasone significantly improved QOL and vomiting control among previously untreated patients receiving MEC, although the efficacy was limited to the reduction of the frequency of CINV. Palonosetron is non-inferior and cost-effective compared to ondansetron for prevention of acute chemotherapy-induced vomiting (CIV) in children receiving moderate and high emetogenic chemotherapy.
- | cisplatin / Generic mfg.
Trial initiation date: Cisplatin Disposition and Kidney Injury (clinicaltrials.gov) - Mar 22, 2019
P=N/A, N=72, Not yet recruiting, Sponsor: University of Colorado, Denver
Palonosetron is non-inferior and cost-effective compared to ondansetron for prevention of acute chemotherapy-induced vomiting (CIV) in children receiving moderate and high emetogenic chemotherapy. Initiation date: Jan 2019 --> Apr 2019
- | cisplatin / Generic mfg.
New trial: Cisplatin Disposition and Kidney Injury (clinicaltrials.gov) - Jan 28, 2019
P=N/A, N=72, Not yet recruiting, Sponsor: University of Colorado, Denver
- | fosaprepitant / Generic mfg.
Enrollment open: A221602: Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Nov 9, 2018
P3, N=690, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Initiation date: Jan 2019 --> Apr 2019 Not yet recruiting --> Recruiting
- | Sustol (granisetron ER) / Heron Therapeutics
Journal: Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron. (Pubmed Central) - Oct 27, 2018
GERSC in a three-drug antiemetic regimen may reduce hydration needs following HEC or MEC. [Formula: see text].
- | oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., palonosetron intravenous / Generic mfg.
Clinical, Journal: A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia. (Pubmed Central) - Oct 21, 2018
To our knowledge, these two drugs have never been described in the literature as a cause of DDPA. We suggest that OIIS in addition to oxaliplatin-induced thrombocytopenia may be associated with the development of DDPAs to other drugs causing clinically significant thrombocytopenia which is important to recognize and manage with discontinuation of provoking agents.
- | fosaprepitant / Generic mfg.
Trial initiation date: A221602: Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Sep 12, 2018
P3, N=690, Not yet recruiting, Sponsor: Alliance for Clinical Trials in Oncology
We suggest that OIIS in addition to oxaliplatin-induced thrombocytopenia may be associated with the development of DDPAs to other drugs causing clinically significant thrombocytopenia which is important to recognize and manage with discontinuation of provoking agents. Initiation date: Jul 2018 --> Oct 2018
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date, Surgery: Compare Between Two Doses of Palonosetron on the Prevention of Postoperative Nausea and Vomiting in Obese Patients (clinicaltrials.gov) - Aug 7, 2018
P4, N=80, Completed, Sponsor: Instituto Nacional de Cancer, Brazil
Initiation date: Jul 2018 --> Oct 2018 Recruiting --> Completed | Trial completion date: Oct 2018 --> Jul 2018
- | fosaprepitant / Generic mfg.
New P3 trial: A221602: Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Jul 5, 2018
P3, N=690, Not yet recruiting, Sponsor: Alliance for Clinical Trials in Oncology
- | Varubi (rolapitant oral) / TerSera Therap, GSK, netupitant (Ro 67-3189) / Helsinn, Otsuka
Review, Journal, CINV: Recent Advances in Preventing Chemotherapy-Induced Nausea and Vomiting. (Pubmed Central) - Jun 22, 2018
The US Food and Drug Administration has recently approved new therapies for prevention of CINV, including the neurokinin-1 (NK1) receptor antagonist rolapitant and the fixed-dose combination of the second-generation 5-hydroxytryptamine type 3 receptor antagonist palonosetron with the novel NK1 receptor antagonist netupitant...This article will address changes in CINV guidelines over the past 5 years and provide updates on recently approved agents and agents that are expected to be approved, based on published phase III trials. It will also explore other factors affecting optimal CINV control, including the role of patient-related risk factors and the role of physician adherence to antiemetic guidelines in reducing the residual risk of CINV.
- | Aloxi (palonosetron oral) / Helsinn, Otsuka, Roche, Eisai, palonosetron intravenous / Generic mfg.
Journal: Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ). (Pubmed Central) - Oct 17, 2017
It will also explore other factors affecting optimal CINV control, including the role of patient-related risk factors and the role of physician adherence to antiemetic guidelines in reducing the residual risk of CINV. Single-dose weekly PAL is a safe and tolerable antiemetic for cRINV prevention in MG patients receiving standard RT and concomitant TMZ.
- | palonosetron intravenous / Generic mfg.
Trial primary completion date, Surgery: Compare Between Two Doses of Palonosetron on the Prevention of Postoperative Nausea and Vomiting in Obese Patients (clinicaltrials.gov) - Aug 29, 2017
P4, N=80, Recruiting, Sponsor: Instituto Nacional de Cancer, Brazil
Single-dose weekly PAL is a safe and tolerable antiemetic for cRINV prevention in MG patients receiving standard RT and concomitant TMZ. Trial primary completion date: Feb 2017 --> Feb 2018
- | Emend intravenous (fosaprepitant) / Merck (MSD), Novartis
Journal: Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study. (Pubmed Central) - May 20, 2017
P2
It is unknown whether the substitution of fosaprepitant for aprepitant provides the same benefit in multi-day cisplatin that was achieved with single-day cisplatin. Trial registration Clinical trial information NCT01736917.
- dexamethasone / Generic mfg., olanzapine / Generic mfg.
New trial: Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of CIN (clinicaltrials.gov) - Nov 22, 2016
P=N/A, N=48, Enrolling by invitation, Sponsor: Hee Jun Kim
- | palonosetron intravenous / Generic mfg.
New P4 trial, Surgery: Compare Between Two Doses of Palonosetron on the Prevention of Postoperative Nausea and Vomiting in Obese Patients (clinicaltrials.gov) - Oct 20, 2016
P4, N=80, Recruiting, Sponsor: Instituto Nacional de Cancer, Brazil
- || Emestop (ramosetron hydrochloride) / Samyang Group
Trial primary completion date: RAPA: Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone (clinicaltrials.gov) - Sep 1, 2016
P4, N=292, Recruiting, Sponsor: Kangdong Sacred Heart Hospital
Trial registration Clinical trial information NCT01736917. Trial primary completion date: Sep 2016 --> Sep 2017
- ||||||| palonosetron intravenous / Generic mfg.
Trial completion, Trial primary completion date: An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting (clinicaltrials.gov) - Jun 2, 2016
P3, N=441, Completed, Sponsor: Helsinn Healthcare SA
Trial primary completion date: Sep 2016 --> Sep 2017 Recruiting --> Completed | Trial primary completion date: Oct 2016 --> Mar 2016
- | Decadron (dexamethasone) / Merck (MSD)
New P4 trial, Surgery: Effectiveness of Triple Therapy With Palonosetron for PON Prophylaxis (clinicaltrials.gov) - Dec 21, 2015
P4, N=40, Completed, Sponsor: Ohio State University
- |||||| palonosetron intravenous / Generic mfg.
Enrollment open: An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting (clinicaltrials.gov) - Oct 27, 2015
P3, N=440, Recruiting, Sponsor: Helsinn Healthcare SA
Recruiting --> Completed | Trial primary completion date: Oct 2016 --> Mar 2016 Not yet recruiting --> Recruiting
- ondansetron intravenous / Generic mfg., dexamethasone injection / Generic mfg., palonosetron intravenous / Generic mfg.
Trial primary completion date: Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients (clinicaltrials.gov) - Oct 22, 2015
P2, N=85, Recruiting, Sponsor: Northside Hospital, Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2015 --> Feb 2016
- |||| Emestop (ramosetron hydrochloride) / Samyang Group
Enrollment open: RAPA: Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone (clinicaltrials.gov) - Sep 24, 2015
P4, N=292, Recruiting, Sponsor: Kangdong Sacred Heart Hospital
Trial primary completion date: Sep 2015 --> Feb 2016 Not yet recruiting --> Recruiting
- |||||||||| palonosetron intravenous / Generic mfg.
New P3 trial: An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting (clinicaltrials.gov) - Sep 22, 2015
P3, N=440, Not yet recruiting, Sponsor: Helsinn Healthcare SA
- ||||| Emestop (ramosetron hydrochloride) / Samyang Group
New P4 trial: RAPA: Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone (clinicaltrials.gov) - Aug 26, 2015
P4, N=292, Not yet recruiting, Sponsor: Kangdong Sacred Heart Hospital
- ondansetron / Generic mfg., morphine sulphate / Generic mfg.
Trial completion: Prevention of Intrathecal Morphine Induced Pruritus: Comparison of Ondansetron and Palonosetron (clinicaltrials.gov) - Apr 1, 2015
P=N/A, N=80, Completed, Sponsor: Kyungpook National University
Not yet recruiting --> Recruiting Recruiting --> Completed
- ondansetron intravenous / Generic mfg., dexamethasone injection / Generic mfg., palonosetron intravenous / Generic mfg.
Trial primary completion date: Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients (clinicaltrials.gov) - Mar 12, 2015
P2, N=85, Recruiting, Sponsor: Northside Hospital, Inc.
Recruiting --> Completed Trial primary completion date: Jun 2015 --> Sep 2015
- | dexamethasone injection / Generic mfg.
Phase classification, Surgery: Efficacy of IV Palo With IV Dexamethasone vs IV Palo for Prevention of Immediate & Delayed PONV (clinicaltrials.gov) - Feb 19, 2015
P4, N=118, Completed, Sponsor: New York University School of Medicine
Trial primary completion date: Jun 2015 --> Sep 2015 Phase classification: P=N/A --> P4
- ondansetron intravenous / Generic mfg., dexamethasone injection / Generic mfg., palonosetron intravenous / Generic mfg.
Trial primary completion date: Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients (clinicaltrials.gov) - Oct 15, 2014
P2, N=85, Recruiting, Sponsor: Northside Hospital, Inc.
Phase classification: P=N/A --> P4 Trial primary completion date: Dec 2014 --> Jun 2015
- | New P2 trial: Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic Patients (clinicaltrials.gov) - Aug 1, 2014
P2, N=134, Recruiting, Sponsor: Associazione Salentina Angela Serra
- ondansetron intravenous / Generic mfg., dexamethasone injection / Generic mfg., palonosetron intravenous / Generic mfg.
Trial primary completion date: Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients (clinicaltrials.gov) - Jun 23, 2014
P2, N=85, Recruiting, Sponsor: Northside Hospital, Inc.
Trial primary completion date: Dec 2014 --> Jun 2015 Trial primary completion date: Aug 2014 --> Dec 2014
- || Inrebic (fedratinib) / BMS
Enrollment change: Effect of SAR302503 on ECG Activity in Patients With Solid Tumors (clinicaltrials.gov) - Jun 2, 2014
P1, N=60, Completed, Sponsor: Sanofi
Trial primary completion date: Aug 2014 --> Dec 2014 N=50 --> 60
- ||| Inrebic (fedratinib) / BMS
Trial completion: Effect of SAR302503 on ECG Activity in Patients With Solid Tumors (clinicaltrials.gov) - Jun 2, 2014
P1, N=60, Completed, Sponsor: Sanofi
N=50 --> 60 Active, not recruiting --> Completed
- ||| palonosetron intravenous / Generic mfg.
Enrollment change: Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED) (clinicaltrials.gov) - May 1, 2014
P4, N=59, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed N=152 --> 59
- | Avastin (bevacizumab) / Roche
Trial termination, Combination therapy, CINV: Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab (clinicaltrials.gov) - Mar 3, 2014
P2, N=63, Terminated, Sponsor: Duke University
N=152 --> 59 Active, not recruiting --> Terminated; Study was halted early after 63 subjects were enrolled due to slow accrual.
- Avastin (bevacizumab) / Roche
Enrollment change, Combination therapy, CINV: Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab (clinicaltrials.gov) - Mar 3, 2014
P2, N=63, Terminated, Sponsor: Duke University
Active, not recruiting --> Terminated; Study was halted early after 63 subjects were enrolled due to slow accrual. N=80 --> 63
- ||||| palonosetron intravenous / Generic mfg.
Enrollment change: Therapeutic Efficacy and Safety of Palonosetron in Treatment of Postoperative Nausea and Vomiting (clinicaltrials.gov) - Dec 23, 2013
P3, N=384, Completed, Sponsor: Samsung Medical Center
N=80 --> 63 N=150 --> 384
- ||||||| palonosetron intravenous / Generic mfg.
Trial completion: Therapeutic Efficacy and Safety of Palonosetron in Treatment of Postoperative Nausea and Vomiting (clinicaltrials.gov) - Dec 23, 2013
P3, N=384, Completed, Sponsor: Samsung Medical Center
N=150 --> 384 Recruiting --> Completed
- Inrebic (fedratinib) / BMS
Enrollment closed: Effect of SAR302503 on ECG Activity in Patients With Solid Tumors (clinicaltrials.gov) - Nov 20, 2013
P1, N=50, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Completed Recruiting --> Active, not recruiting
- | Decadron (dexamethasone) / Merck (MSD)
Trial completion: Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial (clinicaltrials.gov) - Nov 4, 2013
P3, N=1021, Completed, Sponsor: Joseph Roscoe
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| temozolomide / Generic mfg., palonosetron intravenous / Generic mfg.
Enrollment change: Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide (clinicaltrials.gov) - Oct 28, 2013
P2, N=57, Completed, Sponsor: Duke University
Active, not recruiting --> Completed N=40 --> 57
- palonosetron intravenous / Generic mfg.
Trial completion: The Effect of Palonosetron on the QTc Interval During Perioperative Period (clinicaltrials.gov) - Aug 5, 2013
P=N/A, N=100, Completed, Sponsor: Seoul National University Hospital
N=40 --> 57 Recruiting --> Completed
- cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change: Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer (clinicaltrials.gov) - May 6, 2013
P=N/A, N=41, Completed, Sponsor: University of Washington
Recruiting --> Completed N=57 --> 41
- | Inrebic (fedratinib) / BMS
New P1 trial: Effect of SAR302503 on ECG Activity in Patients With Solid Tumors (clinicaltrials.gov) - Apr 18, 2013
P1, N=50, Active, not recruiting, Sponsor: Sanofi
- cisplatin / Generic mfg., fosaprepitant / Generic mfg.
Trial termination, Metastases: Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy (clinicaltrials.gov) - Apr 16, 2013
P2, N=6, Terminated, Sponsor: University of Washington
N=57 --> 41 Completed --> Terminated; Study stopped due to lack of efficacy in first 6 patients
- cisplatin / Generic mfg., fosaprepitant / Generic mfg.
Enrollment change, Metastases: Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy (clinicaltrials.gov) - Apr 16, 2013
P2, N=6, Terminated, Sponsor: University of Washington
Completed --> Terminated; Study stopped due to lack of efficacy in first 6 patients N=45 --> 6
- ||||||| palonosetron intravenous / Generic mfg.
Trial completion, CINV: Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients (clinicaltrials.gov) - Apr 4, 2013
P3, N=494, Completed, Sponsor: Helsinn Healthcare SA
N=45 --> 6 Active, not recruiting --> Completed
- palonosetron intravenous / Generic mfg.
Enrollment change: The Effect of Palonosetron on the QTc Interval During Perioperative Period (clinicaltrials.gov) - Feb 3, 2013
P=N/A, N=100, Completed, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed N=308 --> 100
- |||| temozolomide / Generic mfg., palonosetron intravenous / Generic mfg.
Trial completion: Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide (clinicaltrials.gov) - Jan 15, 2013
P2, N=57, Completed, Sponsor: Duke University
N=308 --> 100 Recruiting --> Completed
- ondansetron / Generic mfg., aprepitant oral / Generic mfg., palonosetron intravenous / Generic mfg.
Clinical: Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC) (clinicaltrials.gov) - Jul 11, 2012
P=N/A, N=40, Completed, Sponsor: Ohio State University Comprehensive Cancer Center